This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts.
Part 1 (dose escalation) will evaluate safety, and determine the maximum tolerated dose of INCB053914 and the recommended phase 2 dose (a tolerated pharmacologically active dose that will be taken forward into Part 2 of the study).
Part 2 (dose expansion) will further evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of the recommended Phase 2 dose.
| SparkCures ID | 774 |
|---|---|
| Trial Phase | Phase 1/2 |
| Enrollment | 145 Patients |
| Treatments | |
| Trial Sponsors |
|
| NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Please visit the ClinicalTrials.gov page for historical site information.
View Centers